Brentuximab vedotin is an anti-CD30 MoAb conjugated with auristatin E, an anti-microtubule agent, and is currently used in CD30+ lymphoproliferative neoplasmas, such as advanced stage or relapsed/refractory Hodgkin lymphoma (HL), systemic anaplastic large cell lymphoma (ALCL), and CD30+ cutaneous T cell lymphomas [155,156]. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.